Search

Your search keyword '"Dent, Susan"' showing total 641 results
Start Over Author "Dent, Susan"
641 results on '"Dent, Susan"'

1. Cardiovascular toxicities of immune therapies for cancer – a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio‐Oncology

Author

Tocchetti, Carlo Gabriele, Farmakis, Dimitrios, Koop, Yvonne, Andres, Maria Sol, Couch, Liam S, Formisano, Luigi, Ciardiello, Fortunato, Pane, Fabrizio, Au, Lewis, Emmerich, Max, Plummer, Chris, Gulati, Geeta, Ramalingam, Sivatharshini, Cardinale, Daniela, Brezden‐Masley, Christine, Iakobishvili, Zaza, Thavendiranathan, Paaladinesh, Santoro, Ciro, Bergler‐Klein, Jutta, Keramida, Kalliopi, de Boer, Rudolf A, Maack, Christoph, Lutgens, Esther, Rassaf, Tienush, Fradley, Michael G, Moslehi, Javid, Yang, Eric H, De Keulenaer, Gilles, Ameri, Pietro, Bax, Jeroen, Neilan, Tomas G, Herrmann, Joerg, Mbakwem, Amam C, Mirabel, Mariana, Skouri, Hadi, Hirsch, Emilio, Cohen‐Solal, Alain, Sverdlov, Aaron L, van der Meer, Peter, Asteggiano, Riccardo, Barac, Ana, Ky, Bonnie, Lenihan, Daniel, Dent, Susan, Seferovic, Petar, Coats, Andrew JS, Metra, Marco, Rosano, Giuseppe, Suter, Thomas, Lopez‐Fernandez, Teresa, and Lyon, Alexander R

Subjects
Cardiorespiratory Medicine and Haematology, Cardiovascular System & Hematology, Cardiovascular medicine and haematology
Abstract

ABSTRACT: The advent of immunological therapies has revolutionized the treatment of solid and haematological cancers over the last decade. Licensed therapies which activate the immune system to target cancer cells can be broadly divided into two classes. The first class are antibodies that inhibit immune checkpoint signalling, known as immune checkpoint inhibitors (ICIs). The second class are cell‐based immune therapies including chimeric antigen receptor T lymphocyte (CAR‐T) cell therapies, natural killer (NK) cell therapies, and tumour infiltrating lymphocyte (TIL) therapies. The clinical efficacy of all these treatments generally outweighs the risks, but there is a high rate of immune‐related adverse events (irAEs), which are often unpredictable in timing with clinical sequalae ranging from mild (e.g. rash) to severe or even fatal (e.g. myocarditis, cytokine release syndrome) and reversible to permanent (e.g. endocrinopathies).The mechanisms underpinning irAE pathology vary across different irAE complications and syndromes, reflecting the broad clinical phenotypes observed and the variability of different individual immune responses, and are poorly understood overall. Immune‐related cardiovascular toxicities have emerged, and our understanding has evolved from focussing initially on rare but fatal ICI‐related myocarditis with cardiogenic shock to more common complications including less severe ICI‐related myocarditis, pericarditis, arrhythmias, including conduction system disease and heart block, non‐inflammatory heart failure, takotsubo syndrome and coronary artery disease. In this scientific statement on the cardiovascular toxicities of immune therapies for cancer, we summarize the pathophysiology, epidemiology, diagnosis, and management of ICI, CAR‐T, NK, and TIL therapies. We also highlight gaps in the literature and where future research should focus.

Published
2024

3. Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique.

Author

Gallagher, Emily, Moore, Heather, Lacouture, Mario, Dent, Susan, Farooki, Azeez, Goncalves, Marcus, Isaacs, Claudine, Johnston, Abigail, Juric, Dejan, Quandt, Zoe, Spring, Laura, Berman, Brian, Decker, Melanie, Hortobagyi, Gabriel, Kaffenberger, Benjamin, Kwong, Bernice, Pluard, Timothy, Rao, Ruta, Schwartzberg, Lee, and Broder, Michael

Abstract

Hyperglycemia and rash are expected but challenging adverse events of phosphatidylinositol-3-kinase inhibition (such as with alpelisib). Two modified Delphi panels were conducted to provide consensus recommendations for managing hyperglycemia and rash in patients taking alpelisib. Experts rated the appropriateness of interventions on a 1-to-9 scale; median scores and dispersion were used to classify the levels of agreement. Per the hyperglycemia panel, it is appropriate to start alpelisib in patients with HbA1c 6.5% (diabetes) to

Published
2024

4. SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy-Related Cardiac Dysfunction.

Author

Avula, Vennela, Sharma, Garima, Kosiborod, Mikhail N, Vaduganathan, Muthiah, Neilan, Tomas G, Lopez, Teresa, Dent, Susan, Baldassarre, Lauren, Scherrer-Crosbie, Marielle, Barac, Ana, Liu, Jennifer, Deswal, Anita, Khadke, Sumanth, Yang, Eric H, Ky, Bonnie, Lenihan, Daniel, Nohria, Anju, Dani, Sourbha S, and Ganatra, Sarju

Abstract

Certain antineoplastic therapies are associated with an increased risk of cardiomyopathy and heart failure (HF). Sodium-glucose cotransporter-2 (SGLT2) inhibitors improve outcomes in patients with HF.This study aims to examine the efficacy of SGLT2 inhibitors in patients with cancer therapy-related cardiac dysfunction (CTRCD) or HF.The authors conducted a retrospective cohort analysis of deidentified, aggregate patient data from the TriNetX research network. Patients aged ≥18 years with a history of type 2 diabetes mellitus, cancer, and exposure to potentially cardiotoxic antineoplastic therapies, with a subsequent diagnosis of cardiomyopathy or HF between January 1, 2013, and April 30, 2020, were identified. Patients with ischemic heart disease were excluded. Patients receiving guideline-directed medical therapy were divided into 2 groups based on SGLT2 inhibitor use. After propensity score matching, odds ratios (ORs) and Cox proportional HRs were used to compare outcomes over a 2-year follow-up period.The study cohort included 1,280 patients with CTRCD/HF (n = 640 per group; mean age: 67.6 years; 41.6% female; 68% White). Patients on SGLT2 inhibitors in addition to conventional guideline-directed medical therapy had a lower risk of acute HF exacerbation (OR: 0.483 [95% CI: 0.36-0.65]; P < 0.001) and all-cause mortality (OR: 0.296 [95% CI: 0.22-0.40]; P = 0.001). All-cause hospitalizations or emergency department visits (OR: 0.479; 95% CI: 0.383-0.599; P < 0.001), atrial fibrillation/flutter (OR: 0.397 [95% CI: 0.213-0.737]; P = 0.003), acute kidney injury (OR: 0.486 [95% CI: 0.382-0.619]; P < 0.001), and need for renal replacement therapy (OR: 0.398 [95% CI: 0.189-0.839]; P = 0.012) were also less frequent in patients on SGLT2 inhibitors.SGLT2 inhibitor use is associated with improved outcomes in patients with CTRCD/HF.

Published
2023

7. COVID-19 severity and cardiovascular outcomes in SARS-CoV-2-infected patients with cancer and cardiovascular disease.

Author

Moey, Melissa, Hennessy, Cassandra, French, Benjamin, Warner, Jeremy, Tucker, Matthew, Hausrath, Daniel, Shah, Dimpy, DeCara, Jeanne, Bakouny, Ziad, Labaki, Chris, Choueiri, Toni, Dent, Susan, Akhter, Nausheen, Ismail-Khan, Roohi, Tachiki, Lisa, Slosky, David, Polonsky, Tamar, Awosika, Joy, Crago, Audrey, Wise-Draper, Trisha, Balanchivadze, Nino, Hwang, Clara, Fecher, Leslie, Gomez, Cyndi, Hayes-Lattin, Brandon, Glover, Michael, Shah, Sumit, Gopalakrishnan, Dharmesh, Griffiths, Elizabeth, Kwon, Daniel, Koshkin, Vadim, Mahmood, Sana, Bashir, Babar, Nonato, Taylor, Razavi, Pedram, McKay, Rana, Nagaraj, Gayathri, Oligino, Eric, Puc, Matthew, Tregubenko, Polina, Wulff-Burchfield, Elizabeth, Xie, Zhuoer, Halfdanarson, Thorvardur, Farmakiotis, Dimitrios, Klein, Elizabeth, Robilotti, Elizabeth, Riely, Gregory, Durand, Jean-Bernard, Hayek, Salim, Kondapalli, Lavanya, Berg, Stephanie, OConnor, Timothy, Bilen, Mehmet, Castellano, Cecilia, Accordino, Melissa, Sibel, Blau, Weissmann, Lisa, Jani, Chinmay, Flora, Daniel, Rudski, Lawrence, Dutra, Miriam, Nathaniel, Bouganim, Ruíz-García, Erika, Vilar-Compte, Diana, Gupta, Shilpa, Morgans, Alicia, and Nohria, Anju

Subjects
COVID-19 outcomes, Cancer, Cardio-oncology, Cardiovascular disease
Abstract

BACKGROUND: Data regarding outcomes among patients with cancer and co-morbid cardiovascular disease (CVD)/cardiovascular risk factors (CVRF) after SARS-CoV-2 infection are limited. OBJECTIVES: To compare Coronavirus disease 2019 (COVID-19) related complications among cancer patients with and without co-morbid CVD/CVRF. METHODS: Retrospective cohort study of patients with cancer and laboratory-confirmed SARS-CoV-2, reported to the COVID-19 and Cancer Consortium (CCC19) registry from 03/17/2020 to 12/31/2021. CVD/CVRF was defined as established CVD or no established CVD, male ≥ 55 or female ≥ 60 years, and one additional CVRF. The primary endpoint was an ordinal COVID-19 severity outcome including need for hospitalization, supplemental oxygen, intensive care unit (ICU), mechanical ventilation, ICU or mechanical ventilation plus vasopressors, and death. Secondary endpoints included incident adverse CV events. Ordinal logistic regression models estimated associations of CVD/CVRF with COVID-19 severity. Effect modification by recent cancer therapy was evaluated. RESULTS: Among 10,876 SARS-CoV-2 infected patients with cancer (median age 65 [IQR 54-74] years, 53% female, 52% White), 6253 patients (57%) had co-morbid CVD/CVRF. Co-morbid CVD/CVRF was associated with higher COVID-19 severity (adjusted OR: 1.25 [95% CI 1.11-1.40]). Adverse CV events were significantly higher in patients with CVD/CVRF (all p

Published
2023

9. Cardiac computed tomographic imaging in cardio-oncology: An expert consensus document of the Society of Cardiovascular Computed Tomography (SCCT). Endorsed by the International Cardio-Oncology Society (ICOS).

Author

Lopez-Mattei, Juan, Yang, Eric H, Baldassarre, Lauren A, Agha, Ali, Blankstein, Ron, Choi, Andrew D, Chen, Marcus Y, Meyersohn, Nandini, Daly, Ryan, Slim, Ahmad, Rochitte, Carlos, Blaha, Michael, Whelton, Seamus, Dzaye, Omar, Dent, Susan, Milgrom, Sarah, Ky, Bonnie, Iliescu, Cezar, Mamas, Mamas A, and Ferencik, Maros

Abstract

Cardio-Oncology is a rapidly growing sub-specialty of medicine, however, there is very limited guidance on the use of cardiac CT (CCT) in the care of Cardio-Oncology patients. In order to fill in the existing gaps, this Expert Consensus statement comprised of a multidisciplinary collaboration of experts in Cardiology, Radiology, Cardiovascular Multimodality Imaging, Cardio-Oncology, Oncology and Radiation Oncology aims to summarize current evidence for CCT applications in Cardio-Oncology and provide practice recommendations for clinicians.

Published
2023

11. Advances in Multimodality Imaging in Cardio-Oncology: JACC State-of-the-Art Review.

Author

Baldassarre, Lauren A, Ganatra, Sarju, Lopez-Mattei, Juan, Yang, Eric H, Zaha, Vlad G, Wong, Timothy C, Ayoub, Chadi, DeCara, Jeanne M, Dent, Susan, Deswal, Anita, Ghosh, Arjun K, Henry, Mariana, Khemka, Abhishek, Leja, Monika, Rudski, Lawrence, Villarraga, Hector R, Liu, Jennifer E, Barac, Ana, and Scherrer-Crosbie, Marielle

Abstract

The population of patients with cancer is rapidly expanding, and the diagnosis and monitoring of cardiovascular complications greatly rely on imaging. Numerous advances in the field of cardio-oncology and imaging have occurred in recent years. This review presents updated and practical approaches for multimodality cardiovascular imaging in the cardio-oncology patient and provides recommendations for imaging to detect the myriad of adverse cardiovascular effects associated with antineoplastic therapy, such as cardiomyopathy, atherosclerosis, vascular toxicity, myocarditis, valve disease, and cardiac masses. Uniquely, we address the role of cardiovascular imaging in patients with pre-existing cardiomyopathy, pregnant patients, long-term survivors, and populations with limited resources. We also address future avenues of investigation and opportunities for artificial intelligence applications in cardio-oncology imaging. This review provides a uniform practical approach to cardiovascular imaging for patients with cancer.

Published
2022

13. Laterality of Radiation Therapy in Breast Cancer is Not Associated With Increased Risk of Coronary Artery Disease in the Contemporary Era

Author

Seth, Lakshya, Makram, Omar, Essa, Amr, Patel, Vraj, Jiang, Stephanie, Bhave, Aditya, Yerraguntla, Sandeep, Gopu, Gaurav, Malik, Sarah, Swaby, Justin, Rast, Johnathon, Padgett, Caleb A., Shetewi, Ahmed, Nain, Priyanshu, Weintraub, Neal, Miller, Eric D., Dent, Susan, Barac, Ana, Shiradkar, Rakesh, Madabhushi, Anant, Ferguson, Catherine, and Guha, Avirup

Published
2024
Full Text
View/download PDF

16. Cardiac Computed Tomography in Cardio-Oncology: JACC: CardioOncology Primer.

Author

Lopez-Mattei, Juan C, Yang, Eric H, Ferencik, Maros, Baldassarre, Lauren A, Dent, Susan, and Budoff, Matthew J

Abstract

Cancer patients and survivors have elevated cardiovascular risk when compared with noncancer patients. Cardio-oncology has emerged as a new subspecialty to comanage and address cardiovascular complications in cancer patients such as heart failure, atherosclerotic cardiovascular disease (ASCVD), valvular heart disease, pericardial disease, and arrhythmias. Cardiac computed tomography (CT) can be helpful in identifying both clinical and subclinical ASCVD in cancer patients and survivors. Radiation therapy treatment planning CT scans and cancer staging/re-staging imaging studies can quantify calcium scores which can identify pre-existing subclinical ASCVD. Cardiac CT can be helpful in the evaluation of cardiac tumors and pericardial diseases, especially in patients who cannot tolerate or have a contraindication to cardiac magnetic resonance. In this review, we describe the optimal utilization of cardiac CT in cancer patients, including risk assessment for ASCVD and identification of cancer treatment-related cardiovascular toxicity.

Published
2021

17. Pertuzumab Cardiotoxicity in Patients With HER2-Positive Cancer: A Systematic Review and Meta-analysis.

Author

Alhussein, Muhammad Mustafa, Mokbel, Abir, Cosman, Tammy, Aghel, Nazanin, Yang, Eric H, Mukherjee, Som D, Dent, Susan, Ellis, Peter M, Dhesy-Thind, Sukhbinder, and Leong, Darryl P

Abstract

Human epidermal growth factor receptor 2 (HER2) overexpressing malignancies, including breast and gastro-esophageal, are associated with a poor prognosis. The cardiotoxicity of trastuzumab, a HER2-targeting monoclonal antibody, is well established. However, the cardiotoxic effect of pertuzumab, another HER2-directed therapy, is less well documented. The objective of this systematic review and meta-analysis was to determine the risk of cardiac events in patients with HER2-positive cancer who are receiving pertuzumab.We performed a systematic review of phase 2 and 3 randomized controlled trials in which the addition of pertuzumab to other standard therapies in patients with stage I-IV HER2-positive cancer was evaluated, and cardiac adverse effects reported. We searched MEDLINE (1946-2020), Embase (1974-2020), and CENTRAL. Two independent reviewers assessed the risk of bias and extracted the data. Risk ratios (RRs) with 95% confidence intervals (CIs) were calculated from the pooled data using the inverse variance method and random-effects models.Eight randomized controlled trials (8420 patients) were included: 1 was gastro-esophageal; 7 were breast cancer trials. Participants' median age ranged from 49 to 61.5 years. All participants received trastuzumab and chemotherapy in addition to pertuzumab or placebo. Compared with placebo, pertuzumab increased the risk of clinical heart failure (HF; RR [95% CI]: 1.97 [1.05-3.70]; I2 = 0%). However, pertuzumab had no demonstrable effect on asymptomatic/minimally symptomatic left ventricular systolic dysfunction (RR [95% CI]: 1.19 [0.89-1.61]; I2 = 19%).Pertuzumab increases the risk of clinical HF, but not asymptomatic/minimally symptomatic left ventricular systolic dysfunction, in HER2-positive cancer patients. Further research into the mechanisms underlying pertuzumab-related HF is needed to understand its clinical spectrum of cardiotoxicity.

Published
2021

20. Priorities in Cardio-Oncology Basic and Translational Science: GCOS 2023 Symposium Proceedings: JACC: CardioOncology State-of-the-Art Review

Author

Salloum, Fadi N., Tocchetti, Carlo G., Ameri, Pietro, Ardehali, Hossein, Asnani, Aarti, de Boer, Rudolf A., Burridge, Paul, Cabrera, José-Ángel, de Castro, Javier, Córdoba, Raúl, Costa, Ambra, Dent, Susan, Engelbertsen, Daniel, Fernández-Velasco, María, Fradley, Mike, Fuster, José J., Galán-Arriola, Carlos, García-Lunar, Inés, Ghigo, Alessandra, González-Neira, Anna, Hirsch, Emilio, Ibáñez, Borja, Kitsis, Richard N., Konety, Suma, Lyon, Alexander R., Martin, Pilar, Mauro, Adolfo G., Mazo Vega, Manuel M., Meijers, Wouter C., Neilan, Tomas G., Rassaf, Tienush, Ricke-Hoch, Melanie, Sepulveda, Pilar, Thavendiranathan, Paaladinesh, van der Meer, Peter, Fuster, Valentin, Ky, Bonnie, and López-Fernández, Teresa

Published
2023
Full Text
View/download PDF

23. Perspectives on the COVID-19 pandemic impact on cardio-oncology: results from the COVID-19 International Collaborative Network survey

Author

Sadler, Diego, DeCara, Jeanne M, Herrmann, Joerg, Arnold, Anita, Ghosh, Arjun K, Abdel-Qadir, Husam, Yang, Eric H, Szmit, Sebastian, Akhter, Nausheen, Leja, Monika, Silva, Carolina Maria Pinto Domingues Carv, Raikhelkar, Jayant, Brown, Sherry-Ann, Dent, Susan, O’Quinn, Rupal, Thuny, Franck, Moudgil, Rohit, Raez, Luis E, Okwuosa, Tochukwu, Daniele, Andres, Bauer, Brenton, Kondapalli, Lavanya, Ismail-Khan, Roohi, Lax, Jorge, Blaes, Anne, Nahleh, Zeina, Elson, Leah, Baldassarre, Lauren A, Zaha, Vlad, Rao, Vijay, Lara, Daniel Sierra, Skurka, Kerry, and on behalf of the Cardio-Oncology International Collaborative Network

Published
2020

24. Cardiovascular care of the oncology patient during COVID-19: An expert consensus document from the ACC Cardio-Oncology and Imaging Councils.

Author

Baldassarre, Lauren A, Yang, Eric H, Cheng, Richard K, DeCara, Jeanne M, Dent, Susan, Liu, Jennifer E, Rudski, Lawrence G, Strom, Jordan B, Thavendiranathan, Paaladinesh, Barac, Ana, Zaha, Vlad G, Bucciarelli-Ducci, Chiara, Ellahham, Samer, Deswal, Anita, Lenneman, Carrie, Villarraga, Hector R, Blaes, Anne H, Ismail-Khan, Roohi, Ky, Bonnie, Leja, Monika J, and Scherrer-Crosbie, Marielle

Abstract

In response to the coronavirus disease 2019 (COVID-19) pandemic, The Cardio-Oncology and Imaging Councils of the American College of Cardiology offers recommendations to clinicians regarding the cardiovascular care of cardio-oncology patients in this expert consensus statement. Cardio-oncology patients-individuals with an active or prior cancer history, and with or at risk of cardiovascular disease-are a rapidly growing population, who are both at increased risk of infection by COVID-19 and experiencing severe and/or lethal complications. Recommendations for optimizing screening and monitoring visits to detect cardiac dysfunction are discussed. In addition, judicious use of multimodality imaging and biomarkers are proposed to identify myocardial, valvular, vascular, pericardial involvement in cancer patients. The difficulties of diagnosing the etiology of cardiovascular complications in patients with cancer and COVID-19 are outlined, along with weighing the advantages against risks of exposure, with the modification of existing cardiovascular treatments and cardiotoxicity surveillance in patients with cancer during the COVID-19 pandemic.

Published
2020

25. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society.

Author

Lyon, Alexander, Dent, Susan, Stanway, Susannah, Earl, Helena, Brezden-Masley, Christine, Cohen-Solal, Alain, Tocchetti, Carlo, Moslehi, Javid, Groarke, John, Bergler-Klein, Jutta, Khoo, Vincent, Tan, Li, Anker, Markus, von Haehling, Stephan, Maack, Christoph, Pudil, Radek, Barac, Ana, Thavendiranathan, Paaladinesh, Ky, Bonnie, Neilan, Tomas, Belenkov, Yury, Rosen, Stuart, Iakobishvili, Zaza, Sverdlov, Aaron, Hajjar, Ludhmila, Macedo, Ariane, Manisty, Charlotte, Ciardiello, Fortunato, Farmakis, Dimitrios, de Boer, Rudolf, Skouri, Hadi, Suter, Thomas, Cardinale, Daniela, Witteles, Ronald, Fradley, Michael, Herrmann, Joerg, Cornell, Robert, Wechelaker, Ashutosh, Mauro, Michael, Milojkovic, Dragana, de Lavallade, Hugues, Ruschitzka, Frank, Coats, Andrew, Seferovic, Petar, Chioncel, Ovidiu, Thum, Thomas, Bauersachs, Johann, Andres, M, Wright, David, López-Fernández, Teresa, Plummer, Chris, and Lenihan, Daniel

Subjects
Cardio-oncology, Cardiotoxicity, Heart failure, Risk factors, Risk prediction, Aged, Androgen Antagonists, Antineoplastic Agents, Cardiovascular Diseases, Female, Heart Disease Risk Factors, Humans, Male, Middle Aged, Neoplasms, Risk Assessment, Risk Factors
Abstract

This position statement from the Heart Failure Association of the European Society of Cardiology Cardio-Oncology Study Group in collaboration with the International Cardio-Oncology Society presents practical, easy-to-use and evidence-based risk stratification tools for oncologists, haemato-oncologists and cardiologists to use in their clinical practice to risk stratify oncology patients prior to receiving cancer therapies known to cause heart failure or other serious cardiovascular toxicities. Baseline risk stratification proformas are presented for oncology patients prior to receiving the following cancer therapies: anthracycline chemotherapy, HER2-targeted therapies such as trastuzumab, vascular endothelial growth factor inhibitors, second and third generation multi-targeted kinase inhibitors for chronic myeloid leukaemia targeting BCR-ABL, multiple myeloma therapies (proteasome inhibitors and immunomodulatory drugs), RAF and MEK inhibitors or androgen deprivation therapies. Applying these risk stratification proformas will allow clinicians to stratify cancer patients into low, medium, high and very high risk of cardiovascular complications prior to starting treatment, with the aim of improving personalised approaches to minimise the risk of cardiovascular toxicity from cancer therapies.

Published
2020

26. Cardio-Oncology Education and Training

Author

Alvarez-Cardona, Jose A, Ray, Jordan, Carver, Joseph, Zaha, Vlad, Cheng, Richard, Yang, Eric H, Mitchell, Joshua D, Stockerl-Goldstein, Keith, Kondapalli, Lavanya, Dent, Susan, Arnold, Anita, Brown, Sherry Ann, Leja, Monica, Barac, Ana, Lenihan, Daniel J, and Herrmann, Joerg

Published
2020

30. Correlation of TILs indices generated by visual review and digital computational algorithm with outcomes from preoperative chemotherapy for TNBC in TBCRC 030.

Author

Nader Marta, Guilherme, primary, Chu, Xiangying, additional, Mukhopadhyay, Satabhisa, additional, Abramson, Vandana G, additional, Brufsky, Adam, additional, Stringer-Reasor, Erica Michelle, additional, Dent, Susan Faye, additional, Traina, Tiffany A., additional, Carey, Lisa A., additional, Rimawi, Mothaffar F., additional, Specht, Jennifer M., additional, Miller, Kathy, additional, Santa-Maria, Cesar Augusto, additional, Dasgupta, Tathagata, additional, Binboğa Kurt, Busem, additional, Tayob, Nabihah, additional, Krop, Ian E., additional, Tung, Nadine M., additional, Schnitt, Stuart J., additional, and Mayer, Erica L., additional

Published
2024
Full Text
View/download PDF

35. Cardiovascular Health

Author

Dent, Susan F., Kikuchi, Robin, Gilchrist, Susan C., Melloni, Chiara, Kimmick, Gretchen G., editor, Shelby, Rebecca A., editor, and Sutton, Linda M., editor

Published
2021
Full Text
View/download PDF

37. Cardioprotective Potential of Sodium-Glucose Co-Transporter-2 Inhibitors in Cancer Patients Treated With Anthracyclines: An Observational Study

Author

Fath, Ayman R., primary, Aglan, Mostafa, additional, Aglan, Amro, additional, Chilton, Robert J., additional, Trakhtenbroit, Anatole, additional, Al-Shammary, Odaye A., additional, Oppong-Nkrumah, Oduro, additional, Lenihan, Daniel J., additional, Dent, Susan F., additional, and Otchere, Prince, additional

Published
2024
Full Text
View/download PDF

38. Relationship between quality of life indicators and cardiac status indicators in chemotherapy patients

Author

Geršak Blaž Matija, Kukec Andreja, Steen Henning, Montenbruck Moritz, Šoštarič Maja, Schwarz Arne Kristian, Esch Sebastian, Kelle Sebastian, Giusca Sorin, Korosoglou Grigorios, Wülfing Pia, Dent Susan, and Lenihan Daniel

Subjects
antineoplastic agents, cardiotoxicity, ventricular function – left, ventricular function – right, quality of life, magnetic resonance imaging, cine, echocardiography, lymphoma, hodgkin disease, breast neoplasms, antineoplastični agensi, kardiotoksičnost, ventrikularna funkcija – levi, ventrikularna funkcija – desni, kakovost življenja, magnetnoresonančno slikanje, video, ehokardiografija, limfomi, hodgkinova bolezen, neoplazme dojk, Public aspects of medicine, RA1-1270
Abstract

With the aim of improving personalized treatment of patients on chemotherapy, the objective of the study was to assess the degree of association between selected Quality of life (QoL) indicators and both clinical and imaging cardiac status indicators when detecting deterioration in QoL of these patients.

Published
2021
Full Text
View/download PDF

39. Cardiovascular Manifestations From Therapeutic Radiation: A Multidisciplinary Expert Consensus Statement From the International Cardio-Oncology Society

Author

Mitchell, Joshua D., Cehic, Daniel A., Morgia, Marita, Bergom, Carmen, Toohey, Joanne, Guerrero, Patricia A., Ferencik, Maros, Kikuchi, Robin, Carver, Joseph R., Zaha, Vlad G., Alvarez-Cardona, Jose A., Szmit, Sebastian, Daniele, Andrés J., Lopez-Mattei, Juan, Zhang, Lili, Herrmann, Jörg, Nohria, Anju, Lenihan, Daniel J., and Dent, Susan F.

Published
2021
Full Text
View/download PDF

40. Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population

Author

De Laurentiis, Michelino, Borstnar, Simona, Campone, Mario, Warner, Ellen, Bofill, Javier Salvador, Jacot, William, Dent, Susan, Martin, Miguel, Ring, Alistair, Cottu, Paul, Lu, Janice, Ciruelos, Eva, Azim, Hamdy A., Chatterjee, Sanjoy, Zhou, Katie, Wu, Jiwen, Menon-Singh, Lakshmi, and Zamagni, Claudio

Published
2021
Full Text
View/download PDF

42. Abstract 11850: Association Between SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Antineoplastic Therapy Associated Cardiomyopathy and Heart Failure

Author

Avula, Vennela, Sharma, Garima, Kosiborod, Mikhail N, Vaduganathan, Muthiah, Neilan, Tomas G, Lopez-Fernandez, Teresa, Dent, Susan F, Baldassarre, Lauren A, Scherrer-Crosbie, Marielle, Scherrer-crosbie, Marielle, Barac, Ana, Liu, Jennifer, Deswal, Anita M, Yang, Eric H, Ky, Bonnie, Lenihan, Daniel, Lenihan, Daniel, Nohria, Anju, Nohria, Anju, Dani, Sourbha, and Ganatra, Sarju

Published
2022
Full Text
View/download PDF

46. Allostatic Load/Chronic Stress and Cardiovascular Outcomes in Patients Diagnosed With Breast, Lung, or Colorectal Cancer.

Author

Stabellini, Nickolas, Cullen, Jennifer, Bittencourt, Marcio S., Moore, Justin X., Sutton, Arnethea, Nain, Priyanshu, Hamerschlak, Nelson, Weintraub, Neal L., Dent, Susan, Meng-Han Tsai, Banerjee, Amitava, Ghosh, Arjun K., Sadler, Diego, Coughlin, Steven S., Barac, Ana, Shanahan, John, Montero, Alberto J., and Guha, Avirup

Published
2024
Full Text
View/download PDF

47. Discovery Considerations Presented by Group Collaboration Tools

Author

Hite, Collin, Simpson, Heather, and Dent, Susan

Subjects
Instant messaging, Instant messaging technology, Law
Abstract

Displaced by the COVID-19 pandemic, corporate workforces quickly transitioned watercooler banter and board meetings from the office into cyberspace. In many ways, the implementation of digital collaboration tools, such as [...]

Published
2021

48. Breast cancer risk reduction: Beyond pharmacologic intervention.

Author

Dent, Susan, Tumlinson, Robin, Guha, Avirup, and Moore, Heather

Subjects
*BREAST cancer, *SOCIAL determinants of health, *WOMEN'S mortality, *DISEASE risk factors, *RISK sharing
Abstract

Breast cancer and cardiovascular disease share common risk factors, and are responsible for significant morbidity and mortality in women in North America. Nonpharmacologic approaches such as lifestyle modifications can decrease this risk but may be constrained by social determinants of health. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

49. Low-touch, team-based care for co-morbidity management in cancer patients: the ONE TEAM randomized controlled trial

Author

Zullig, Leah L., Shahsahebi, Mohammad, Neely, Benjamin, Hyslop, Terry, Avecilla, Renee A. V., Griffin, Brittany M., Clayton-Stiglbauer, Kacey, Coles, Theresa, Owen, Lynda, Reeve, Bryce B., Shah, Kevin, Shelby, Rebecca A., Sutton, Linda, Dinan, Michaela A., Zafar, S. Yousuf, Shah, Nishant P., Dent, Susan, and Oeffinger, Kevin C.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results